» Articles » PMID: 10089505

Incorporation of Prior Phase Information Strengthens Maximum-likelihood Structure Refinement

Overview
Specialty Chemistry
Date 1999 Mar 25
PMID 10089505
Citations 99
Authors
Affiliations
Soon will be listed here.
Abstract

The application of a maximum-likelihood analysis to the problem of structure refinement has led to striking improvements over the traditional least-squares methods. Since the method of maximum likelihood allows for a rational incorporation of other sources of information, we have derived a likelihood function that incorporates experimentally determined phase information. In a number of different test cases, this target function performs better than either a least-squares target or a maximum-likelihood function lacking prior phases. Furthermore, this target gives significantly better results compared with other functions incorporating phase information. When combined with a procedure to mask 'unexplained' density, the phased likelihood target also makes it possible to refine very incomplete models.

Citing Articles

Design of high-affinity binders to immune modulating receptors for cancer immunotherapy.

Yang W, Hicks D, Ghosh A, Schwartze T, Conventry B, Goreshnik I Nat Commun. 2025; 16(1):2001.

PMID: 40011465 PMC: 11865580. DOI: 10.1038/s41467-025-57192-z.


Molecular basis of interchain disulfide-bond formation in BMP-9 and BMP-10.

Schwartze T, Morosky S, Rosato T, Henrickson A, Lin G, Hinck C bioRxiv. 2024; .

PMID: 39464140 PMC: 11507788. DOI: 10.1101/2024.10.14.618187.


Design of High Affinity Binders to Convex Protein Target Sites.

Yang W, Hicks D, Ghosh A, Schwartze T, Conventry B, Goreshnik I bioRxiv. 2024; .

PMID: 38746206 PMC: 11092582. DOI: 10.1101/2024.05.01.592114.


Structural study of UFL1-UFC1 interaction uncovers the role of UFL1 N-terminal helix in ufmylation.

Banerjee S, Varga J, Kumar M, Zoltsman G, Rotem-Bamberger S, Cohen-Kfir E EMBO Rep. 2023; 24(12):e56920.

PMID: 37988244 PMC: 10702826. DOI: 10.15252/embr.202356920.


SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy.

Drilon A, Sharma M, Johnson M, Yap T, Gadgeel S, Nepert D Cancer Discov. 2023; 13(8):1789-1801.

PMID: 37269335 PMC: 10401072. DOI: 10.1158/2159-8290.CD-23-0361.